ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions.

# The Supreme Court yesterday approved the Securities Commission’s bid to relegate its $221.55m claim against FTX behind those of the insolvent crypto exchange’s clients and other victims.

The Securities Commission of The Bahamas (SCB) has assessed $221.55 million in regulatory penalties against FTX Digital ...

Supreme Court Sanctions Agreement for FTX DM Joint Official Liquidators to Subordinate Securities Commission of The Bahamas’ $221.55 Million Regulatory Penalties Claim ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), a leader in RNA interference (RNAi) therapeutics, stands at a pivotal juncture as it seeks to capitalize on the burgeoning market for ...

The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

ENDEAR is one of the two pivotal studies that formed the basis of regulatory approval for [nusinersen] 12 mg." According to results of the study previously announced by Biogen, the higher-dose cohort ...

In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of its Ionis-partnered therapy Spinraza for spinal muscular atrophy will be ...

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 2 ...